Vanessa Ira

Vanessa Ira is the senior managing editor for GU Oncology Now and Cancer Nursing Today. She regularly edits and writes for both brands’ websites.

Articles by Vanessa Ira

Vanessa IraASCO 2022 | June 7, 2022
The findings are notable for a patient population that has limited treatment options.
Read More
Vanessa IraASCO 2022 | June 7, 2022
Cell-free DNA (cfDNA) methylation may be used to predict treatment response in patients with muscle-invasive bladder cancer.
Vanessa IraASCO 2022 | June 7, 2022
The TheraP ANZUP 1603 trial showed both options were suitable for men with mCRPC.
Vanessa IraASCO 2022 | June 7, 2022
The treatment was also compared to an active comparator of non-steroidal anti-androgen.
Vanessa IraASCO 2022 | June 3, 2022
Researchers hypothesized that switch maintenance therapy with the TKI would improve outcomes for the metastatic disease.
Vanessa IraASCO 2022 | June 3, 2022
The data were from a randomized phase-2 study assessing new treatment combinations in patients with advanced clear cell RCC.
Vanessa IraASCO 2022 | June 3, 2022
The findings could lead to improved outcomes in men with PSMA PET-positive mCRPC.
Vanessa IraASCO 2022 | June 3, 2022
Researchers found it had clinical efficacy regardless of patients' prior treatment or standard of care chosen.
Vanessa IraASCO 2022 | June 3, 2022
The results mean that progression-free survival endpoints could be used to expediate phase-3 clinical trials.
Vanessa IraASCO 2022 | June 3, 2022
The rate of relapses occurring 2 or 5 years after disease-free survival is low among testicular cancer patients, study finds.